Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Current Quarter	$-0.85	Next Quarter	$-0.81
Current Year	$-3.59	Next Year	$-2.42
QoQ Growth	+4.7%	YoY Growth	+32.6%
3Y EPS CAGR	N/A	Target Price	$12.57
Consensus	Buy	Upside	+23.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REPL	$10.18	+3.14%	1.31M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REPL	$10.18	+3.1%	1.31M
3
4
5
6

REPL

REPL

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Replimune Group Inc. Data in Excel

Get Replimune Group Inc. Data in Excel